ADMA Biologics, Inc.
ADMAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the. At a $2.02B market cap, ADMA Biologics, Inc. ranks as a mid-cap company within healthcare. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Market Cap
$2.02B
Beta
0.73
P/E (TTM)
13.00
P/E (Fwd)
8.84
EPS (TTM)
$0.67
EPS (Fwd)
$0.98
ROE
43.3%
ROA
22.0%
Cash
$55.92B
Total Debt
$97.67B
Free CF
$58.4M
52W Change
-47.9%
Annual Financials
Cash vs Debt
ADMA Biologics, Inc. carries $97.67B in total debt against $55.92B in cash reserves — debt is roughly 1.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $58.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 43.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 22.0% further supports the picture of efficient asset utilization. Revenue has grown from $154.1M (2022) to $510.2M (2025), reflecting a 231% increase over the period.
Investors considering ADMA Biologics, Inc. should weigh the typical risks associated with ADMA's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing ADMA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.